Facts and myths on recurrent vulvovaginal candidosis - A review on epidemiology, clinical manifestations, diagnosis, pathogenesis and therapy

International Journal of STD and AIDS

Volumn 13, Issue 8, 2002, Pages 522-539

  Mardh P A ^a   Rodrigues, A G ^b   Genc M ^c   Novikova, N ^d   Martinez De Oliveira, J ^e   Guaschino, S ^f  

^a LUND UNIVERSITY   (Sweden)

^b Porto School of Nursing   (Portugal)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d BOGOMOLETS NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^e Porto Medical School   (Portugal)

^f UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Diagnosis; Epidemiology; Pathogenesis; Recurrent vulvovaginal candidosis; Therapy

Indexed keywords

ANTIFUNGAL AGENT; BUTOCONAZOLE; CLOTRIMAZOLE; ECONAZOLE; FENTICONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NYSTATIN; ORAL CONTRACEPTIVE AGENT; TERCONAZOLE; TIOCONAZOLE;

ALLERGY; BEHAVIOR MODIFICATION; CANDIDA ALBICANS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL FEATURE; FUNGUS CULTURE; HEART FAILURE; HOST PARASITE INTERACTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; OBESITY; ORAL CONTRACEPTION; PATHOPHYSIOLOGY; PERSONAL HYGIENE; PH MEASUREMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SEXUAL BEHAVIOR; SMOKING; STRESS; VAGINA CANDIDIASIS;

ANTIFUNGAL AGENTS; CANDIDIASIS, VULVOVAGINAL; FEMALE; HUMANS; RECURRENCE;

EID: 0036315884     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646202760159639     Document Type: Review

References (189)

1. Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis
2. Recurrent vulvovaginal candidiasis
3. Vulvovaginal candidiasis: Epidemiologic, diagnostic and therapeutic considerations
4. Epidemiology of recurrent vulvovaginal candidiasis: Identification and strain differentiation of Candida albicans
5. Repeated candidiasis: Reinfection or recrudescence
6. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy
7. Torulopsis glabrata vaginitis
8. Risk factors for vulvovaginal candidiasis: A case-control study among university students
9. Prevalence of Candida albicans in the vaginal fluid of Portuguese women
10. Candidosis of the genitalia
11. Candida dubliensis: Characteristics and identification
12. Saccharomyces cerevisae vaginitis: Transmission from yeast used in baking
13. Treatment of vaginal mycosis with clotrimazole
14. Pathogenic mechanisms in recurrent genital candidosis in women
15. Recurrent vulvovaginal candidiasis, what we know and what we don't
16. Pathogenesis and treatment of recurrent vulvovaginal candidiasis
17. Rvvc - A puzzling condition
18. Factors that predispose the host to candidosis
19. Clinical and microbiological characteristics of symptomatic vulvovaginal candidiasis in HIV-seropositive women
20. Chronic vaginal candidiasis in women with human immunodeficiency virus infection
21. Is vulvovaginal candidiasis an AIDS-related illness?
22. Comparison of strain specificity of yeast from various organs of women with vaginal candidiasis
23. Recurrent vaginal candidiasis. Importance of an intestinal reservoir
24. Use of rDNA restriction fragment length polymorphisms to differentiate strains of Candida albicans in women with vulvovaginal candidiasis
25. Evolution and replacement of Candida albicans strains during recurrent vaginitis demonstrated by DNA fingerprinting
26. Vulvovaginal candidiasis: Clinical manifestations, risk factors, management algorithm
27. Sexual behaviour of women with repeated episodes of vulvovaginal candidiasis
28. History, clinical findings, sexual behavior and hygiene habits in women with and without recurrent episodes of urinary symptoms
29. Storage of specimens at 4°C or addition of sodium fluoride (1%), prevents formation of ethanol in urine inoculated with Candida albicans
30. In vitro production of ethanol in urine by fermentation
31. Current problems in the diagnosis and treatment of Candida vaginitis
32. The limited value of symptoms and signs in the diagnosis of vaginal infections
33. Who are the women that present with a history suggestive of RVVC and with current symptoms mimicking an attack of the condition, but who remains unproven as genital carriers of Candida by culture studies?
34. What are the signs and symptoms in women with RVVC caused by Candida albicans and non-albicans strains and do they differ from Candida culture-negative cases with a history suggestive of RVVC?
35. Chronic fungal vaginitis: The value of cultures
36. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida crusei, and Candida (Torulopsis) glabrata
37. Comparison of the Quantum II, API Yeast Ident, and AutoMicrobic systems for identification of clinical yeast isolates
38. Comparison of three commercial media for direct identification and discrimination of Candida species in clinical specimens
39. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species
40. Evaluation of CHROMagar Candida for rapid screening of clinical specimens for Candida species
41. Fluconazole-resistant yeast with chromogenic agar
42. Evaluating vaginal pH. Accuracy of two commercial pH papers in comparison to a hand-held digital pH-meter
43. Vaginal colonization by Candida in symptomatic women with and without a history of recurrent vulvovaginal candidiasis
44. Diagnosing vaginal candidosis by a slide latex agglutination test
45. Nonspecific vaginitis: Diagnostic criteria and microbiological and epidemiological findings
46. Bacterial vaginosis a threat to reproductive health? - Perspectives, current controversies and research demands
47. Can in vitro observations explain interactions in vivo between a lactobacillus-dominated vaginal flora, bacterial vaginosis and vulvovaginal candidosis (VVC)
48. Asymptomatic bacterial vaginosis: Response to therapy
49. Vaginal microbiological flora and sexually transmitted diseases in women with recurrent and current vulvovaginal candidosis
50. Is lack of concurrence of bacterial vaginosis and candidosis explained by presence of bacterial amines?
51. Vaginal lactobacillosis
52. Cytolytic vaginosis
53. Epidemiologic characteristic of women with idiopathic RVVC
54. Pathogenesis of candidosis
55. WO-2, a stable aneuploid derivative of Candida albicans strains WO-1, can switch from white to opaque and form hyphae
56. Analysis of secreted aspartic proteinases from Candida albicans: Purification and characterization of individual Sap 1, Sap 2 and Sap 3 isoenzymes
57. High-frequency switching in Candida strains isolated from vaginitis patients
58. Differences in adhesion of Candida albicans 3153A cells exhibiting switch phenotypes to buccal epithelium and stratum corneum
59. Germ tube formation changes surface hydrophobicity of Candida cells
60. Germ tube formation by Candida albicans impair phagocytosis performance by human polymorphonuclear leucocytosis
61. Adherence of Candida albicans to human vaginal and buccal epithelial cells
62. Human genital candidosis. Histochemistry, scanning and transmission electron microscopy
63. Isolation of variant of Candida albicans
64. Ketoconazole prophylaxis in experimental vaginal candidiasis
65. Management of recurrent vulvovaginal candidiasis with intermittent ketokonazole prophylaxis
66. Phagocytosis of Candida albicans by polymorphonuclear leukocytes from normal and diabetic subjects
67. Quantitative analysis of opsonophagocytosis and of killing of Candida albicans by human peripheral blood leukocytes by using flow cytometry
68. Enhancement of germ tube formation in Candida albicans by b-endorphin
69. Inhibition of germ tube formation by Candida albicans by local anesthetics: An effect related to ionic channel blockade
70. The pH of the host niche controls gene expression in and virulence of Candida albicans
71. Gene regulation during high-frequency switching in Candida albicans
72. Variation in adhesion and cell surface hydrophobicity in Candida albicans white and opaque phenotypes
73. Characterization and solubilization of antigens expressed primarily on the surface of germ tubes of Candida albicans by immunofluorescence
74. Structures involved in the binding of human fibrinogen to Candida albicans germ tubes
75. Characterization of binding of human fibrinogen to the surface of germ tubes and mycelium of Candida albicans
76. Role of fibronectin in the pathogenesis of candidal infections
77. Interaction of Candida albicans with genital mucosal surfaces: Involvement of fibronectin in adherence
78. Binding of plasma proteins to Candida species in vitro
79. In vitro effect of fibrinogen on Candida albicans germ tube formation
80. Regulatory effect of fibronectin on the morphogenesis of Candida albicans
81. Effect of a crude extract of protein produced by lactobacilli on germ tube formation by Candida albicans
82. Extracellular polymer of Candida albicans: Isolation, analysis and role in adhesion
83. Oestrogen-binding protein in Candida albicans: Antibody development and cellular localization by electron immunocytochemistry
84. Identification of two germ-tube-specific cell wall antigens of Candida albicans
85. Demonstration and solubilization of antigens expressed primarily on the surfaces of Candida albicans germ tubes
86. Purification and properties of three intracellular proteinases from Candida albicans
87. Secretion of iducible proteinase by pathogenic Candida species
88. Evidence for a correlation between proteinase secretion and vulvovaginal candidiasis
89. Cell wall and secreted proteins of Candida albicans: Identification, function and expression
90. Biological and chemical characterization of toxic substances from Candida albicans
91. Oral contraceptive use and vaginal candida colonization
92. Recurrent vulvovaginal candidiasis associated with long-term tamoxifen treatment in postmenopausal women
93. Mycotic vaginitis in pregnancy: A double evaluation of the susceptibility to the main antimycotic drugs of isolated species
94. Suppression of anti-candida activity of murine neutrophils by progesterone in vitro: A possible mechanism in pregnant women's vulnerability to vaginal candidiasis
95. Progesterone influences germ tube formation and cell division of Candida species
96. The impact of oral contraception on vulvovaginal candidiasis
97. Is the "pill" a cause of vaginal candidiasis? Culture study
98. The incidence of Candida albicans in the vagina of "healthy young women". How often do they have symptoms? Possible etiological factors
99. The impact of contraceptive methods on the onset of symptomatic vulvovaginal candidiasis within the menstrual cycle
100. Use of nonoxynol-9 and changes in vaginal lactobacilli
101. The spermicidal compound nonoxynol-9 increases adhesion of Candida species to human epithelial cell in vitro
102. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora
103. The epidemiology of vulvovaginal candidiasis; risk factors
104. Comparison of the influence of spermicidal and non-spermicidal contraception on bacterial vaginosis, candidal infection and inflammation of the vagina - A preliminary study
105. Candidiasis in women fitted with an intrauterine contraceptive device
106. Toxicity of copper (CuSO4) on Candida species
107. Colonization of Candida of extragenital sites in cases with recurrent vulvovaginal candidiasis (RVVC). Reservoirs for recolonization of genital tract before and after therapy
108. Characterization of women assumed to suffer from recurrent vulvovaginal candidosis
109. Impaired tolerance for glucose in women with recurrent vaginal candidosis
110. Candidal infections and populations of Candida albicans in mouths of diabetics
111. Limited effect of refined carbohydrate dietary supplementation on colonization of the gastrointestinal tract of healthy subjects by Candida albicans
112. Modulating effect of dietary, carbohydrate supplementation on Candida albicans colonization and invasion in a neutropenic mouse model
113. Recurrent candidiasis and "malcarbohydrate metabolism"
114. Bacterial vaginosis and smoking
115. Candida cell wall mannan: A polysaccharide with diverse immunological properties
116. Systematic cell-mediated immune reactivity, in women with recurrent vulvovaginal candidiasis
117. The role of cell-mediated immunity in candidiasis
118. Immunological findings in patients with chronically recurrent vaginal candidosis and new therapeutical approaches
119. Immunopathogenesis of recurrent vulvovaginal candidiasis
120. New insights into the immune pathogenesis of recurrent vulvovaginal candidiasis
121. Cellular immunity of patients with recurrent or refractory vulvovaginal moniliasis
122. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody
123. Recurrent allergic vulvovaginitis: Treatment with Candida albicans allergen immunotherapy
124. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel adjuvant, LT (R192), against systematic candidiasis
125. Idiopathic intravaginal vaccination to protect against candidal vaginitis by secretory, yeast-killer toxin-like anti-idiotypic antibodies
126. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection
127. Vaginal heat shock protein expression in symptom free women with history of recurrent vulvovaginitis
128. Circulating heat shock proteins in women with recurrent vulvovaginitis
129. Immunology of recurrent vaginitis
130. Immunologic factors influencing susceptibility to recurrent candidal vulvovaginitis
131. Circulating heat shock proteins in women with a history of recurrent vulvovaginitis
132. Candida albicans: Cellular immune system interactions during different stages of the menstrual cycle
133. An C3b receptor on Candida albicans: Structure, function and correlates for pathogenicity
134. Zinc status in women with recurrent vulvovaginal candidiasis
135. Zinc levels of serum and cervicovaginal secretions in RVVC
136. Vaginal eosinophils and IgE antibodies to Candida albicans in women with recurrent vaginitis
137. A localized vaginal allergic response in women with recurrent vaginitis
138. Recurrent vaginitis as a result of sexual transmission of IgE antibodies
139. Recurrent vaginal candidiasis and allergic rhinitis: A common association
140. Latex allergy: A primary care primer
141. Hyposensitisation in the management of recurring vaginal candidiasis
142. Recurrent and persistent vulvovaginal candidiasis treatment with ketokonazole
143. A prospective study to assess the efficacy of ketoconazole in the treatment of recurrent vaginal candidiasis
144. A lower rate of preterm birth after clotrimazole therapy during pregnancy
145. Prophylactic treatment of recurrent vaginal mycosis with clotrimazole
146. Comparison of econazole and clotrimazole in the treatment of vulvovaginal candidiasis
147. Recurrent vaginal candidosis: Prospective study of effectiveness of maintenance miconazole treatment
148. Recurrence of vulvovaginal candidosis during pregnancy. Comparison of miconazole vs nystatin treatment
149. Itraconazole in the treatment of vaginal candidosis and the effect of treatment of the sexual partner
150. Role of antifungai drug resistance in the pathogenesis of recurrent vulvovaginal candidiasis
151. Oral fluconazole for vaginal candidiasis
152. Persistent vulvovaginal candidiasis: Systematic treatment with oral fluconazole
153. Use of local antibiotic combination in the treatment of mycotic vaginitis and mixed vaginitis
154. Flucytosine: A review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
155. No teratogenic effect after clotrimazole therapy during pregnancy
156. Antifungal activity of boric acid on vaginal Candida species
157. Resistens mot Candida. Redan ett bekymmer
158. Resistance of yeasts to azole-derivative antifungals
159. Targeted gene disruption in Candida albicans wild-type strains: The role of the MDR1 gene in fluconazole resistance of clinical Candida isolates
160. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
161. Detection of resistance to fluconazole in Candida strains due to efflux pumps, using cytometric methods
162. Occurrence and the sensitivity to drugs of fungi other than Candida albicans isolated from vagina
163. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis
164. Nystatin versus boric acid powder in vulvovaginal candidiasis
165. Boric acid treatment of vulvovaginal candidiasis
166. Efficacy of maintenance therapy with topical boric acid in comparison with oral itraconazole treatment of recurrent vulvovaginal candidiasis
167. In vitro activity of essential oils, in particular Melaleuca alternifolia (tea tree) oil and tea tree oil products, against Candida spp.
168. Warning against a fashionable cure for vulvovaginitis. Tea tree oil may substitute Candida itching with allergy itching
169. Consumption patterns of antifungal drugs reflecting the epidemiology of vulvovaginal candidosis
170. Antifungal effect of ibuprofen alone and in combination with fluconazole against Candida species
171. Antifungal activity of local anesthetics against Candida species
172. In vitro effect of local anesthetics on Candida albicans germ tube formation
173. 2-producing lactobacilli to bacterial vaginosis in pregnant women
174. Vulvovaginal candidiasis complicating recurrent bacterial vaginosis
175. Quantitative relationships of Candida albicans infections and dressing patterns in Nigerian women
176. Vulvovaginal candidiasis in female sex workers
177. Microwave sterilization of Candida on underwear fabric. A preliminary report
178. Survival of Candida albicans on fabric after laundering
179. Sugar chromatography studies in recurrent Candida vulvovaginitis
180. The association between dietary intake and reported history of Candida vulvovaginitis
181. Ingestion of yoghurt containing Lactobacillus acidophilus as prophylaxis for candidal vaginitis
182. Ingestion of yoghurt containing Lactobacillus acidophilus compared with pasteurized yoghurt as prophylaxis for recurrent candidal vaginitis and bacterial vaginosis
183. Co-treatment of the male partner in vaginal candidosis: A double-blind randomized control study
184. Vulvovaginal candidiasis
185. What to do with patient with RVVC?